All Stories

  1. B cells and atherosclerosis in systemic lupus erythematosus

    Article • Expert Review of Clinical Immunology, January 2019, Taylor & Francis

    Professor Michael Koutsilieris, Dr Clio P Mavragani

  2. TNFAIP3 F127C Coding Variation in Greek Primary Sjogren’s Syndrome Patients

    Article • Journal of Immunology Research, December 2018, Hindawi Publishing Corporation

    Professor Michael Koutsilieris, Eli Gkioka, Dr Clio P Mavragani

  3. Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations

    Article • Arthritis Care & Research, December 2015, Wiley

    Dr Clio P Mavragani

  4. Clinical and Laboratory Predictors of Distinct Histopathogical Features of Lupus Nephritis

    Article • Medicine, May 2015, Wolters Kluwer Health

    Dr Clio P Mavragani

  5. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren’s syndrome: prevalence, clinical and laboratory associations

    Article • Arthritis Research & Therapy, April 2015, Springer Science + Business Media

    Dr Clio P Mavragani, Professor Michael Koutsilieris

  6. Predicting the Outcome of Sjogren’s Syndrome-Associated Non-Hodgkin’s Lymphoma Patients

    Article • PLoS ONE, February 2015, PLOS

    Dr Clio P Mavragani, Dimitrios Ziogas

  7. Sjögren’s Syndrome

    Article • January 2015, Elsevier

    Dr Clio P Mavragani

  8. SAT0023 Clinical and Laboratory Predictors of Distinct Histological Classes of Lupus Nephritis-Can They Substitute the Renal Biopsy?

    Article • Annals of the Rheumatic Diseases, June 2014, BMJ

    Dr Clio P Mavragani

  9. THU0243 Proper Initiation of Biologic Treatment (TREAT-TO-TARGET STRATEGY) Favors Better Outcome in Patients with Rheumatoid Arthritis

    Article • Annals of the Rheumatic Diseases, June 2014, BMJ

    Dr Clio P Mavragani

  10. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome

    Article • Journal of Autoimmunity, June 2014, Elsevier

    Dr Clio P Mavragani, Professor Michael Koutsilieris

  11. SAT0128 Biologic Treatment is Associated with More Serious Adverse Reactions, Serious Infections and Admissions in Hospital than DMARDS in Patients with Rheumatoid Arthritis: A REAL World Study

    Article • Annals of the Rheumatic Diseases, June 2014, BMJ

    Dr Clio P Mavragani

  12. FRI0001 Good Response after Three Months of Treatment with Biologic Agents May PREDICT Long-Term Efficacy of Biologic Treatment in Patients with Rheumatoid Arthritis

    Article • Annals of the Rheumatic Diseases, June 2014, BMJ

    Dr Clio P Mavragani

  13. Elevated IgG4 Serum Levels Among Primary Sjögren's Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease?

    Article • Arthritis Care & Research, April 2014, Wiley

    Dr Clio P Mavragani

  14. Sjogren syndrome

    Article • Canadian Medical Association Journal, February 2014, Canadian Medical Association (CMA)

    Dr Clio P Mavragani

  15. Sjögren's Syndrome

    Article • Annual Review of Pathology Mechanisms of Disease, January 2014, Annual Reviews

    Dr Clio P Mavragani

  16. Sjögren’s Syndrome

    Article • January 2014, Elsevier

    Dr Clio P Mavragani

  17. Sjögren’s Syndrome

    Article • January 2014, Springer Science + Business Media

    Dr Clio P Mavragani

  18. Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome

    Article • Genes & Immunity, October 2013, Springer Science + Business Media

    Dr Clio P Mavragani

  19. New advances in the classification, pathogenesis and treatment of Sjogrenʼs syndrome

    Article • Current Opinion in Rheumatology, September 2013, Wolters Kluwer Health

    Dr Clio P Mavragani

  20. THU0325 Elevated IgG4 Serum Levels Among Primary Sjogren’s Syndrome Patients: Do they Unmask Underlying IgG4-Related Disease?

    Article • Annals of the Rheumatic Diseases, June 2013, BMJ

    Dr Clio P Mavragani

  21. THU0012 BAFF Genetic Variants in Lymphomagenesis Associated with Sjogren’s Syndrome

    Article • Annals of the Rheumatic Diseases, June 2013, BMJ

    Dr Clio P Mavragani, Professor Michael Koutsilieris

  22. AB0233 Type I interferon and clinical phenotype in idiopathic inflammatory myopathies

    Article • Annals of the Rheumatic Diseases, June 2013, BMJ

    Dr Clio P Mavragani

  23. THU0137 Effectiveness and Adverse Reactions of Long-Term Use of Biologic Agents in Patients with Rheumatoid Arthritis: A Retrospective Study

    Article • Annals of the Rheumatic Diseases, June 2013, BMJ

    Dr Clio P Mavragani

  24. Treatment of dry eyes in Sjögren's syndrome: the role of autologous blood serum

    Article • Expert Opinion on Orphan Drugs, May 2013, Informa Healthcare

    Dr Clio P Mavragani

  25. Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations

    Article • Frontiers in Immunology, January 2013, Frontiers

    Dr Clio P Mavragani

  26. Endocrine alterations in primary Sjogren's syndrome: An overview

    Article • Journal of Autoimmunity, December 2012, Elsevier

    Dr Clio P Mavragani

  27. Brief Report: Adrenal autoimmunity in primary Sjögren's syndrome

    Article • Arthritis & Rheumatism, November 2012, Wiley

    Dr Clio P Mavragani

  28. Ocular actions of platelet-activating factor: clinical implications

    Article • Expert Opinion on Therapeutic Targets, August 2012, Informa Healthcare

    Dr Clio P Mavragani, Professor Michael Koutsilieris

  29. Linear IgA dermatosis in a patient with primary Sjogren's syndrome

    Article • Rheumatology, July 2012, Oxford University Press (OUP)

    Dr Clio P Mavragani

  30. Cytotoxics or biologicals in the treatment of Sjögren’s syndrome?

    Article • International Journal of Clinical Rheumatology, February 2012, OMICS Publishing Group

    Dr Clio P Mavragani

  31. Adult Onset Still's Disease and Autoinflammation

    Article • International Journal of Inflammation, January 2012, Hindawi Publishing Corporation

    Dr Clio P Mavragani

  32. Adult-Onset Still’s Disease: From Pathophysiology to Targeted Therapies

    Article • International Journal of Inflammation, January 2012, Hindawi Publishing Corporation

    Dr Clio P Mavragani, Professor Michael Koutsilieris

  33. Autoimmune Disorders - Pathogenetic Aspects

    Article • October 2011, IntechOpen

    Dr Clio P Mavragani

  34. Subclinical Atherosclerosis in Systemic Autoimmune Disorders

    Article • October 2011, IntechOpen

    Dr Clio P Mavragani

  35. Activation of the type I interferon pathway in primary Sjögrenʼs syndrome

    Article • Current Opinion in Rheumatology, September 2011, Wolters Kluwer Health

    Dr Clio P Mavragani

  36. Role of Asymmetrical Dimethylarginine in Inflammation-Induced Endothelial Dysfunction in Human Atherosclerosis

    Article • Hypertension, April 2011, Wolters Kluwer Health

    Dr Clio P Mavragani, Professor Michael Koutsilieris

  37. Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma

    Article • Scandinavian Journal of Rheumatology, March 2011, Taylor & Francis

    Dr Clio P Mavragani

  38. Cardiovascular Involvement

    Article • January 2011, Springer Science + Business Media

    Dr Clio P Mavragani

  39. Pulmonary Involvement

    Article • January 2011, Springer Science + Business Media

    Dr Clio P Mavragani

  40. Classic Immunosuppressive and Immunomodulatory Drugs

    Article • January 2011, Springer Science + Business Media

    Dr Clio P Mavragani

  41. Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus: Association with Distinct Clinical Phenotypes

    Article • Journal of Biomedicine and Biotechnology, January 2011, Hindawi Publishing Corporation

    Dr Clio P Mavragani

  42. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome

    Article • Arthritis Research & Therapy, January 2011, Springer Science + Business Media

    Dr Clio P Mavragani

  43. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study

    Article • November 2010, Springer Science + Business Media

    Dr Clio P Mavragani

  44. Activation of the type I interferon pathway in primary Sjogren’s syndrome

    Article • Journal of Autoimmunity, November 2010, Elsevier

    Dr Clio P Mavragani

  45. Psychopathological and personality features in primary Sjogren's syndrome--associations with autoantibodies to neuropeptides

    Article • Rheumatology, June 2010, Oxford University Press (OUP)

    Dr Clio P Mavragani

  46. The geoepidemiology of Sjögren's syndrome

    Article • Autoimmunity Reviews, March 2010, Elsevier

    Dr Clio P Mavragani

  47. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: A post hoc analysis of a predominantly Hispanic cohort

    Article • Arthritis & Rheumatism, February 2010, Wiley

    Dr Clio P Mavragani

  48. Antithyroid antibodies in antiphospholipid syndrome: prevalence and clinical associations

    Article • Lupus, September 2009, SAGE Publications

    Dr Clio P Mavragani

  49. Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome

    Article • The Journal of Rheumatology, July 2009, The Journal of Rheumatology

    Dr Clio P Mavragani

  50. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies

    Article • Annals of the Rheumatic Diseases, December 2008, BMJ

    Dr Clio P Mavragani

  51. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade

    Article • Annals of the Rheumatic Diseases, July 2008, BMJ

    Dr Clio P Mavragani

  52. Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case–control study

    Article • Annals of the Rheumatic Diseases, February 2008, BMJ

    Dr Clio P Mavragani

  53. Sa.18. The Type I IFN Signature Determines the Sustained Anti-citrullinated Protein Antibody Levels During TNFα Blockade in Rheumatoid Arthritis

    Article • Clinical Immunology, January 2008, Elsevier

    Dr Clio P Mavragani, Professor Paul Peter Tak

  54. Sa.23. Nucleosomes, but Not Type I Interferons, Contribute to the Induction of Anti-nuclear Antibodies by TNF Alpha Blockade in Spondyloarthritis

    Article • Clinical Immunology, January 2008, Elsevier

    Dr Clio P Mavragani, Professor Paul Peter Tak

  55. Augmented interferon-α pathway activation in patients with Sjögren's syndrome treated with etanercept

    Article • Arthritis & Rheumatism, December 2007, Wiley

    Dr Clio P Mavragani

  56. Conventional Therapy of Sjogren’s Syndrome

    Article • Clinical Reviews in Allergy & Immunology, September 2007, Springer Science + Business Media

    Dr Clio P Mavragani

  57. Activation of type I interferon in systemic lupus erythematosus

    Article • Expert Review of Clinical Immunology, July 2007, Taylor & Francis

    Dr Clio P Mavragani

  58. A novel mutation of the familial Mediterranean fever gene in a Greek family related to a non-classical, variably expressed FMF phenotype

    Article • Rheumatology International, June 2007, Springer Science + Business Media

    Dr Clio P Mavragani

  59. Rheumatoid arthritis: correlation between rheumatoid factor levels and CA-125 tumour marker elevation

    Article • Annals of the Rheumatic Diseases, February 2007, BMJ

    Dr Clio P Mavragani

  60. Analysis ofSAA1gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis

    Article • Amyloid, January 2007, Taylor & Francis

    Dr Clio P Mavragani

  61. Systemic Autoimmune Manifestations: When Should Underlying Thyroid Autoimmunity be Considered?

    Article • Current Rheumatology Reviews, November 2006, Bentham Science Publishers

    Dr Clio P Mavragani

  62. The management of Sjögren's syndrome

    Article • Nature Clinical Practice Rheumatology, May 2006, Springer Science + Business Media

    Dr Clio P Mavragani

  63. Infliximab in Takayasu arteritis: a safe alternative?

    Article • Clinical Rheumatology, April 2006, Springer Science + Business Media

    Dr Clio P Mavragani

  64. Retroperitoneal fibrosis and c-ANCA positivity

    Article • Clinical Rheumatology, December 2005, Springer Science + Business Media

    Dr Clio P Mavragani

  65. Alleviation of polyarticular syndrome in multicentric reticulohistiocytosis with intravenous zoledronate

    Article • Annals of the Rheumatic Diseases, October 2005, BMJ

    Dr Clio P Mavragani

  66. Is polydipsia sometimes the cause of oxcarbazepine-induced hyponatremia?

    Article • European Journal of Internal Medicine, August 2005, Elsevier

    Dr Clio P Mavragani

  67. Immunsuppression und Immunmodulation beim Sjögren-Syndrom - Was ist bewiesen? Lindert sie die Sicca-Symptome?

    Article • Aktuelle Rheumatologie, February 2005, Thieme Publishing Group

    Dr Clio P Mavragani

  68. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion

    Article • Rheumatology, November 2004, Oxford University Press (OUP)

    Dr Clio P Mavragani

  69. Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

    Article • Thrombosis and Haemostasis, September 2004, Schattauer GmbH

    Dr Clio P Mavragani

  70. Nervous System Involvement in Sjogren's Syndrome

    Article • January 2004, Elsevier

    Dr Clio P Mavragani

  71. Cutaneous ulcers: An unusual manifestation of inherited thrombophilia

    Article • American Journal of Hematology, January 2004, Wiley

    Dr Clio P Mavragani

  72. Lupus nephritis: current issues

    Article • Annals of the Rheumatic Diseases, September 2003, BMJ

    Dr Clio P Mavragani

  73. Pure red cell aplasia in a Sjögren's syndrome/lupus erythematosus overlap patient

    Article • American Journal of Hematology, March 2003, Wiley

    Dr Clio P Mavragani

  74. Sjögren’s Syndrome: Autoantibodies to Cellular Antigens

    Article • International Archives of Allergy and Immunology, January 2000, Karger Publishers

    Dr Clio P Mavragani

  75. Recurrent pregnancy loss and autoantibody profile in autoimmune diseases

    Article • Rheumatology, December 1999, Oxford University Press (OUP)

    Dr Clio P Mavragani

  76. Rheumatoid arthritis in the elderly

    Article • Experimental Gerontology, June 1999, Elsevier

    Dr Clio P Mavragani

  77. Pregnancy outcome and anti-Ro/SSA in autoimmune diseases: a retrospective cohort study

    Article • Rheumatology, July 1998, Oxford University Press (OUP)

    Dr Clio P Mavragani